{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-001956","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.084384+00:00","generated_at":"2026-06-27T04:57:11.829442+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cyclerion reports FY2021 net loss $51.6M; MELAS topline data expected Q2 2022","bullets":["Net loss $51.6M for FY2021 vs $77.8M in FY2020; cash $54M at Dec 31, 2021.","R&D expense $37.6M (down from $56.4M); G&A $20.6M (down from $28.8M).","Phase 2a MELAS trial enrollment closed; topline data expected in Q2 2022.","Phase 1b CIAS trial enrollment ongoing; topline expected H2 2022; Phase 2a ADv trial initiated.","Bruce Kinon appointed VP Clinical Development; collaboration with Ariana Pharma for AI biomarker discovery."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-001956","json":"https://secwatch.observer/filing/0000950170-22-001956.json","markdown":"https://secwatch.observer/filing/0000950170-22-001956.md","text":"https://secwatch.observer/filing/0000950170-22-001956.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000095017022001956/0000950170-22-001956-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000095017022001956/cycn-20220224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:57:11.829442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}